Spanish biotech ALLOX has closed a €9.4 million ($10.5 million) seed round, led by Asabys with participation from Spanish and Catalan public investors, to expand its experimental biology and AI platform for targeting “difficult-to-drug” protein-protein interactions and gene-regulating transcription factors. The company has also appointed former Novo Holdings executive Morten Graugaard as independent chair of its board.
